Dov Perlysky Net Worth

The estimated Net Worth of Dov Perlysky is at least $227 Thousand dollars as of 14 January 2019. Mr. Perlysky owns over 9,184 units of Enzo Biochem stock worth over $73,024 and over the last 12 years he sold ENZ stock worth over $0. In addition, he makes $154,375 as Lead Independent Director at Enzo Biochem.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Perlysky ENZ stock SEC Form 4 insiders trading

Dov has made over 3 trades of the Enzo Biochem stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 9,184 units of ENZ stock worth $24,797 on 14 January 2019.

The largest trade he's ever made was exercising 59,455 units of Enzo Biochem stock on 31 October 2017 worth over $171,230. On average, Dov trades about 5,617 units every 31 days since 2013. As of 14 January 2019 he still owns at least 65,787 units of Enzo Biochem stock.

You can see the complete history of Mr. Perlysky stock trades at the bottom of the page.

Dov Perlysky biography

Dov Perlysky CPA serves as Lead Independent Director of the Company. He is currently a member of the Company’s Audit, Compensation and Nominating/Governance Committees. Mr. Perlysky became the chairman of the Compensation Committee in 2017. Mr. Perlysky has been a member of the Board of Directors of Pharma-Bio Serv, Inc. since 2004, and was a former Director of Highlands State Bank until their sale to Lakeland Bank. Mr. Perlysky has also been the managing member of Nesher, LLC, a private investment firm, since 2000 and was a director of Engex, Inc., a closed-end mutual fund and News Communications. Mr. Perlysky was a vice president in the private client group of Laidlaw Global Securities, a registered broker-dealer. Mr. Perlysky received his Bachelor of Science in Mathematics and Computer Science from the University of Illinois in 1985 and his Master of Management from the J.L. Kellogg School of Management of Northwestern University in 1991. ), other current and past board positions and finance background, making him well qualified as a member of our Board.

What is the salary of Dov Perlysky?

As the Lead Independent Director of Enzo Biochem, the total compensation of Dov Perlysky at Enzo Biochem is $154,375. There are 9 executives at Enzo Biochem getting paid more, with Elazar Rabbani having the highest compensation of $1,487,800.

How old is Dov Perlysky?

Dov Perlysky is 58, he's been the Lead Independent Director of Enzo Biochem since 2019. There are 5 older and 8 younger executives at Enzo Biochem. The oldest executive at Enzo Biochem, Inc. is Dr. Elazar Rabbani Ph.D., 78, who is the Co-Founder, Chairman, Chief Scientific Officer & Sec..

What's Dov Perlysky's mailing address?

Dov's mailing address filed with the SEC is C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK, NY, 10022.

Insiders trading at Enzo Biochem

Over the last 22 years, insiders at Enzo Biochem have traded over $2,615,763 worth of Enzo Biochem stock and bought 1,070,494 units worth $3,103,461 . The most active insiders traders include Bradley Louis Radoff, Management Corp Harbert Dis..., and Elazar Rabbani. On average, Enzo Biochem executives and independent directors trade stock every 127 days with the average trade being worth of $59,099. The most recent stock trade was executed by Kara Cannon on 21 February 2024, trading 10,640 units of ENZ stock currently worth $11,810.

What does Enzo Biochem do?

enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.

Complete history of Mr. Perlysky stock trades at Enzo Biochem

Enzo Biochem executives and stock owners

Enzo Biochem executives and other stock owners filed with the SEC include:

• Elazar Rabbani,
  Chairman of the Board, Chief Executive Officer, Secretary
• Barry Weiner,
  President, Treasurer
• Dr. Elazar Rabbani Ph.D.,
  Co-Founder, Chairman, Chief Scientific Officer & Sec.
• Barry W. Weiner,
  Founder, Treasurer & Pres
• Dieter Schapfel,
  Chief Medical Director - Enzo Clinical Labs
• Kara Cannon,
  Chief Commercial Officer
• Dr. Dieter Schapfel M.D.,
  Chief Medical Director of Enzo Clinical Labs
• David Bench,
  Chief Financial Officer, Principal Accounting Officer
• David A. Bench,
  CFO & Principal Accounting Officer
• Dov Perlysky,
  Lead Independent Director
• Rebecca Fischer,
  Independent Director
• Ian Walters,
  Independent Director
• Mary Tagliaferri,
  Independent Director
• Kara Cannon,
  Chief Commercial Officer
• Hamid Erfanian,
  CEO & Director
• Bruce A. Dey,
  VP of Sales & Marketing - Enzo Clinical Labs
• Gregory M. Bortz,
  Director
• Bernard L Kasten,
  Director
• David C Goldberg,
  VP CorpDev Pres Enz Clin Labs
• Steven J Pully,
  Director
• Bruce A. Hanna,
  Director
• James Michael O'brien,
  EVP of Finance
• Peter J Iv Clemens,
  10% owner
• Management Corp Harbert Dis...,
  
• Stanford S Warshawsky,
  Director
• Fabian Blank,
  Director
• Christine Fischette,
  Pres., Enzo Therapeutics, Inc.
• Irwin Gerson,
  Director
• John Delucca,
  Director
• Stephen B H Kent,
  Director
• Dean Engelhardt,
  Executive Vice President
• Melvin F Lazar,
  Director
• Barbara E Thalenfeld,
  VP Corporate Development
• John B Sias,
  Director
• Carl W Balezentis,
  Pres., Enzo Life Sciences
• Kevin Krenitsky,
  President, Enzo Clinical Labs
• Shahram K Rabbani,
  COO, Treasurer & Secretary
• Norman E Kelker,
  Senior Vice President
• Herbert B Bass,
  VP of Finance
• Andrew P Whiteley,
  VP BusDev-COO Enzo Lif Sci Inc
• Bradley Louis Radoff,
  Director
• James G. Wolf,
  
• Hamid Erfanian,
  Chief Executive Officer
• Patricia Eckert,
  Chief Financial Officer